NanoViricides, Inc. (NNVC)
USD 1.08
(0.93%)
USD 1.08
(0.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 12.82 Million USD | -24.12% |
| 2023 | 16.89 Million USD | -28.07% |
| 2022 | 23.49 Million USD | -22.36% |
| 2021 | 30.26 Million USD | 26.54% |
| 2020 | 23.91 Million USD | 77.82% |
| 2019 | 13.44 Million USD | -27.49% |
| 2018 | 18.54 Million USD | -31.32% |
| 2017 | 27 Million USD | -26.29% |
| 2016 | 36.63 Million USD | -17.09% |
| 2015 | 44.18 Million USD | -0.86% |
| 2014 | 44.56 Million USD | 171.64% |
| 2013 | 16.4 Million USD | 4.98% |
| 2012 | 15.62 Million USD | 45.28% |
| 2011 | 10.75 Million USD | 19.64% |
| 2010 | 8.99 Million USD | 199.62% |
| 2009 | 3 Million USD | 104.41% |
| 2008 | 1.46 Million USD | 8.74% |
| 2007 | 1.35 Million USD | -50.53% |
| 2006 | 2.72 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 15.41 Million USD | -8.78% |
| 2024 Q4 | 12.82 Million USD | 11.84% |
| 2024 Q3 | 11.46 Million USD | -14.46% |
| 2024 Q2 | 13.4 Million USD | -13.07% |
| 2023 FY | 16.89 Million USD | -28.07% |
| 2023 Q3 | 18.57 Million USD | -8.65% |
| 2023 Q2 | 20.33 Million USD | -7.91% |
| 2023 Q1 | 22.08 Million USD | -6.01% |
| 2023 Q4 | 16.89 Million USD | -9.03% |
| 2022 FY | 23.49 Million USD | -22.36% |
| 2022 Q2 | 26.8 Million USD | -8.12% |
| 2022 Q4 | 23.49 Million USD | -6.56% |
| 2022 Q3 | 25.14 Million USD | -6.21% |
| 2022 Q1 | 29.17 Million USD | -3.58% |
| 2021 FY | 30.26 Million USD | 26.54% |
| 2021 Q2 | 28.08 Million USD | -11.81% |
| 2021 Q1 | 31.84 Million USD | 33.18% |
| 2021 Q3 | 32.76 Million USD | 16.65% |
| 2021 Q4 | 30.26 Million USD | -7.63% |
| 2020 Q3 | 16.52 Million USD | 42.26% |
| 2020 Q2 | 11.61 Million USD | -1.43% |
| 2020 FY | 23.91 Million USD | 77.82% |
| 2020 Q1 | 11.78 Million USD | -12.36% |
| 2020 Q4 | 23.91 Million USD | 44.69% |
| 2019 Q2 | 15 Million USD | -13.62% |
| 2019 FY | 13.44 Million USD | -27.49% |
| 2019 Q1 | 17.37 Million USD | -6.34% |
| 2019 Q3 | 15.39 Million USD | 2.6% |
| 2019 Q4 | 13.44 Million USD | -12.64% |
| 2018 Q4 | 18.54 Million USD | -16.98% |
| 2018 Q2 | 23.72 Million USD | -6.09% |
| 2018 Q3 | 22.33 Million USD | -5.84% |
| 2018 Q1 | 25.26 Million USD | -6.43% |
| 2018 FY | 18.54 Million USD | -31.32% |
| 2017 FY | 27 Million USD | -26.29% |
| 2017 Q4 | 27 Million USD | -5.52% |
| 2017 Q3 | 28.57 Million USD | -8.88% |
| 2017 Q2 | 31.36 Million USD | -8.35% |
| 2017 Q1 | 34.22 Million USD | -6.58% |
| 2016 Q1 | 42.29 Million USD | -4.27% |
| 2016 Q2 | 40.84 Million USD | -3.43% |
| 2016 Q3 | 38.31 Million USD | -6.2% |
| 2016 Q4 | 36.63 Million USD | -4.4% |
| 2016 FY | 36.63 Million USD | -17.09% |
| 2015 Q3 | 45.6 Million USD | -4.21% |
| 2015 Q1 | 49.01 Million USD | 9.98% |
| 2015 FY | 44.18 Million USD | -0.86% |
| 2015 Q4 | 44.18 Million USD | -3.1% |
| 2015 Q2 | 47.6 Million USD | -2.88% |
| 2014 Q3 | 40.94 Million USD | 78.91% |
| 2014 FY | 44.56 Million USD | 171.64% |
| 2014 Q4 | 44.56 Million USD | 8.84% |
| 2014 Q1 | 25.11 Million USD | 53.05% |
| 2014 Q2 | 22.88 Million USD | -8.85% |
| 2013 Q3 | 17.87 Million USD | 14.5% |
| 2013 Q1 | 14.35 Million USD | -8.16% |
| 2013 FY | 16.4 Million USD | 4.98% |
| 2013 Q4 | 16.4 Million USD | -8.21% |
| 2013 Q2 | 15.61 Million USD | 8.77% |
| 2012 Q2 | 13.56 Million USD | 9.57% |
| 2012 Q1 | 12.37 Million USD | 15.05% |
| 2012 Q4 | 15.62 Million USD | 8.72% |
| 2012 FY | 15.62 Million USD | 45.28% |
| 2012 Q3 | 14.37 Million USD | 6.01% |
| 2011 FY | 10.75 Million USD | 19.64% |
| 2011 Q4 | 10.75 Million USD | 9.12% |
| 2011 Q3 | 9.85 Million USD | -11.63% |
| 2011 Q2 | 11.15 Million USD | 14.15% |
| 2011 Q1 | 9.77 Million USD | 8.69% |
| 2010 Q3 | 4.51 Million USD | -19.59% |
| 2010 FY | 8.99 Million USD | 199.62% |
| 2010 Q2 | 5.6 Million USD | 0.68% |
| 2010 Q4 | 8.99 Million USD | 99.36% |
| 2010 Q1 | 5.57 Million USD | 85.65% |
| 2009 Q2 | 3.14 Million USD | -24.36% |
| 2009 Q4 | 3 Million USD | 16.75% |
| 2009 FY | 3 Million USD | 104.41% |
| 2009 Q1 | 4.15 Million USD | 182.78% |
| 2009 Q3 | 2.57 Million USD | -18.15% |
| 2008 Q1 | 3.09 Million USD | 129.43% |
| 2008 Q2 | 2.5 Million USD | -19.12% |
| 2008 Q3 | 1.88 Million USD | -24.59% |
| 2008 Q4 | 1.46 Million USD | -22.3% |
| 2008 FY | 1.46 Million USD | 8.74% |
| 2007 Q3 | 1 Million USD | -38.87% |
| 2007 Q2 | 1.63 Million USD | -20.94% |
| 2007 FY | 1.35 Million USD | -50.53% |
| 2007 Q1 | 2.07 Million USD | -24.06% |
| 2007 Q4 | 1.35 Million USD | 34.8% |
| 2006 Q4 | 2.72 Million USD | 0.0% |
| 2006 FY | 2.72 Million USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | 33.838% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -123.55% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 88.339% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 84.256% |
| Azitra, Inc. | 5.11 Million USD | -150.667% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -28.37% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -13202.957% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -27.985% |
| CEL-SCI Corporation | 30.52 Million USD | 57.997% |
| iBio, Inc. | 28.73 Million USD | 55.374% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 87.306% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -69.461% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 80.446% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -193.321% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -41.94% |
| Oragenics, Inc. | 4.96 Million USD | -158.195% |
| BiomX Inc. | 58.15 Million USD | 77.951% |
| BiomX Inc. | 58.15 Million USD | 77.951% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 84.813% |
| Palatin Technologies, Inc. | 10.74 Million USD | -19.368% |
| Scorpius Holdings, Inc. | 51.03 Million USD | 74.876% |
| Theriva Biologics, Inc. | 60.21 Million USD | 78.703% |